News summarySEC EDGARNov 4, 2026, 12:00 PM
SEC 8-K filed 2026-11-04 (items 2.02, 9.01)
earningsequity_marketsregulatory_actioncorporate_earnings
EX-99.1 2 ef20084542_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update 3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year 3Q 2026 Adjusted Net Income (1) of $51.1 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Basic EPS of $0.22, Increasing 47% Year-over-Year 3Q 2026 Adjusted Basic EPS (2) of $0.23, Increasing 44% Year-over-Year 3Q 2026 Adjusted EBITDA